The 8 most recent market catalysts affecting $SNY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 16, 2026
Corporate Catalyst
Bullish
Impact 65
Sanofi Inaugurates $925M Flu Vaccine Facility In Toronto, Canada To Strengthen Pandemic Preparedness
Sanofi has opened a major new flu vaccine manufacturing facility in Toronto, a $925 million investment partly funded by the Canadian and Ontario governments. This is significant as…
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 65
European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent Indication
Sanofi (SNY) has withdrawn its European regulatory application for Dupixent to treat moderate-to-severe bullous pemphigoid. This decision was prompted by the European Medicines Age…
Aug 18, 2026
Corporate Catalyst
Bearish
Impact 55
EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24
Sanofi Winthrop Industrie has formally withdrawn its application to the EMA for Dupixent (dupilumab) to treat moderate-to-severe bullous pemphigoid in adults. This means the drug w…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Sanofi Secures EU Approval For MenQuadfi In Infants From Six Weeks, Backed By Immunogenicity Data From Pivotal MET58 Study
This EU approval for Sanofi's MenQuadfi vaccine in infants significantly expands its addressable market, particularly in a high-value segment. The positive immunogenicity data from…
Jul 30, 2026
Corporate Catalyst
Bearish
Impact 85
Sanofi shares are trading lower after the company reported Q2 financial results and issued FY26 sales guidance below estimates.
Sanofi's lower-than-expected Q2 results and, more critically, the downward revision of its FY26 sales guidance, are a direct negative catalyst for the company. This suggests challe…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 92
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate
Sanofi's Q2 results show a substantial beat on both adjusted EPS and sales estimates, with EPS up 34.44% year-over-year and sales up 18.98%. This indicates strong underlying busine…
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 85
Sanofi Drops Dupixent Successor Candidate After Assessing Data
Sanofi's decision to discontinue amlitelimab, a potential successor to its blockbuster drug Dupixent, is a significant negative catalyst. While the drug showed durable response in …
Jul 24, 2026
Corporate Catalyst
Neutral
Impact 75
Sanofi Discontinues Amlitelimab Development In Atopic Dermatitis, Will Not Submit For Global Regulatory Reviews After Strategic Pipeline Assessment
Sanofi's discontinuation of Amlitelimab for atopic dermatitis is a negative catalyst for the company, as it removes a potential blockbuster drug from its late-stage pipeline. This …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.